TITLE

Telavancin OK'd After Long Road to Approval

PUB. DATE
September 2009
SOURCE
Bioworld Week;9/21/2009, Vol. 17 Issue 38, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the approval given by the U.S. Food and Drug Administration (FDA) to an application filed by Theravance Inc. and Astellas Pharma US Inc. for telavancin. It states that the telavancin is the first lipoglycopeptide to gain approval and expected to be in the hospital-acquired pneumonia market. It adds that the drug is designed to treat adults with complicated skin and skin structure infection (cSSSI) through daily injectable antibiotic.
ACCESSION #
44369824

 

Related Articles

  • Theravance: Telavancin Approvable In CSSSI.  // Bioworld Week;10/29/2007, Vol. 15 Issue 44, p3 

    The article reports on the approval received by Theravance Inc. and Astellas Pharma US Inc. for telavancin, a once-daily, injectable antibiotic, from the Food & Drug Administration (FDA) in the U.S. Telavancin is indicated for complicated skin and skin structure infections (cSSSI) caused by...

  • Decisions Update.  // PharmaWatch: Biotechnology;Oct2009, Vol. 8 Issue 10, p12 

    The article offers developments related drug approval decisions. Shire Pharmaceuticals Group PLC has obtained the approval from the U.S. Food and Drug Administration (FDA) for Intuniv for attention-deficit/hyperactivity disorder (ADHD). Theravance Inc. and Astellas Pharma US Inc. unveiled that...

  • Theravance: Telavancin Approvable In CSSSI. Boggs, Jennifer // BioWorld Today;10/23/2007, Vol. 18 Issue 206, p1 

    The article reports on the U.S. Food and Drug Administration's (FDA) approval of the injectable antibiotic telavancin from Theravance Inc. and partner Astellas Pharma US Inc. The drug is indicated for the treatment of complicated skin and skin structure infections caused by Gram-positive...

  • FDA approves pharmacologic stress agent. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;5/15/2008, Vol. 65 Issue 10, p890 

    The article reports on the marketing approval granted by the U.S. Food and Drug Administration (FDA) on regadenoson injection or Lexiscan developed by CV Therapeutics Inc. and Astellas Pharma US Inc. It relates that the drug is used as a pharmacologic stress agent on patients undergoing...

  • There's a new option for treating systemic fungal infections. LoBuono, Charlotte // Drug Topics;4/18/2005, Vol. 149 Issue 8, p22 

    This article reports the approval of micafungin from Astellas Pharma Inc. by the U.S. Food and Drug Administration. It is indicated for injection for the treatment of patients with esophageal candidiasis. The company plans to launch the product in the market within the next month. Micafungin is...

  • Telavancin OK'd After Long, Painful Road to Approval. Young, Donna // BioWorld Today;9/15/2009, Vol. 20 Issue 177, p1 

    The article reports on the approval granted by the U.S. Food and Drug Administration (FDA) to the application filed by Theravance Inc. and Astellas Pharma US Inc. for televancin, an injectable antibiotic used to treat adults with complicated skin and skin structure infections (cSSSI) caused by...

  • Second indication granted for hyponatremia drug.  // Drug Topics;3/19/2007, Vol. 151 Issue 6, p10 

    The article explains that the U.S. Food and Drug Administration (FDA) has granted its approval to Astellas Pharma's injectable vaprisol drug Conivaptan for the treatment of in-patients with hypervolemic hyponatremia. Conivaptan has previously received approval for treatment of euvolemic...

  • Prograf gains indication.  // MPR - Urologists' Edition;Fall2009/Winter2010, Vol. 6 Issue 2, pA4 

    The article reports on the U.S. Food and Drug Administration (FDA) approval received by Astellas Pharma US Inc. for its Prograf (tacrolimus) drug in 2009. Prograf has received approval to prevent organ rejection for recipients in kidney transplant. Prograf is already showed for the prophylaxis...

  • FDA Panel Backs Approval of Telavancin.  // Bioworld Week;11/24/2008, Vol. 16 Issue 47, p4 

    The article reports on the support of the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) on its approval of Theravance Inc.'s injectable antibiotic, televancin, despite the potency of the drug to cause birth defects and kidney problems. Theravance and Astellas...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics